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Thromboxane receptor blockade reduces renal injury in murine lupus
nephritis. To investigate the role of thromboxane A2 (TxA2) in murine
lupus, we assessed the effects of the specific thromboxane receptor
antagonist GR32191 on immune complex glomerulonephritis in MRL-
lpr/lpr mice. Forty mg/kg/day GR32191 was given by twice daily
subcutaneous injection for eight weeks beginning at 12 weeks of age.
This dose completely blocked the renal vasoconstnction produced by
the thromboxane agonist U466l9. After eight weeks of treatment, both
glomerular filtration rate (GFR) (8.9 0.6 vs. 6.8 1.1 mI/mm/kg; P
<0.05) and PAH clearance (CPAH) (37.4 2.5 vs. 29.9 3.3 mI/mm/kg;
P <0.05) were significantly higher in mice given GR32191 compared to
vehicle treated animals. Administration of GR32191 also reduced pro-
teinuria from 18.1 11.6 to 3.7 1.3 mg/24 hours (P <0.05). In
GR32191 treated MRL-lpr/lpr mice, renal hemodynamic function and
proteinuria were not significantly different from congenic MRL-+/+
controls. Thromboxane receptor blockade had striking affects on renal
histomorphology reducing both hyaline thrombi in glomeruli (P =
0.022) and interstitial inflammation (P 0.006). Glomerular crescents
and severity of vasculitis also tended to be reduced in mice receiving
the thromboxane receptor antagonist. The overall histopathologic score
in mice given GR32191 was significantly lower than vehicle treated
animals (4.7 0.5 vs. 8.4 1.5; P = 0.016). These effects of GR32191
were associated with decreased excretion of thromboxane B2 (TxB2) in
urine (292 37 vs. 747 155 pg/24 hr; P <0.005) as well as a modest
reduction in glomerular deposits of IgG (semiquantitative score 2.6
0.2 vs. 3.5 0.2; P <0.02). Thus, chronic thromboxane receptor
blockade markedly altered the course of renal disease in MRL-lprflpr
mice, suggesting that TxA2 is an important mediator of renal dysfunc-
tion and injury in this murine model of lupus nephritis.
TxA2 is a labile arachidonic acid metabolite with a number of
biologic actions that may be relevant to the pathogenesis of
renal disease. Within the kidney, TxA2 decreases renal blood
flow [1—31 and stimulates mesangial cell contraction [4, 5].
These alterations could, in turn, reduce glomerular ultrafiltra-
tion [6]. TxA2 also causes platelet aggregation [7]. Intrarenal
platelet aggregation and subsequent release of growth factors
may stimulate cellular proliferation and increase production of
extracellular matrix proteins [8—10]. Finally, TxA2 directly
stimulates production of extracellular matrix proteins in vitro
[11]. Thus, TxA2 could promote renal hemodynamic dysfunc-
tion and injury by a variety of mechanisms.
Recent studies have implicated TxA2 in the pathogenesis of
renal disease in systemic lupus erythematosus (SLE) [12—16].
For example, renal thromboxane production is increased in the
MRL-lpr/lpr and (NZB x NZW)F1 murine models of lupus
nephritis [13, 14]. In these models, enhanced renal thrombox-
ane production correlates directly with proteinuria as well as
the severity of renal pathology [13]. In MRL-lpr/lpr mice, acute
thromboxane receptor blockade significantly reverses renal
hemodynamic impairment [14]. TxA2 may also be important in
humans with lupus nephritis. Patrono et al [15] found increased
urinary excretion of TxB2 (the stable hydrolysis product of
TxA2) in SLE patients with acute renal disease as well as a
significant inverse correlation between urinary TxB2 and creat-
mine clearance. Furthermore, short-term infusions of a throm-
boxane receptor antagonist transiently improved renal function
in patients with biopsy-proven renal SLE [16]. Together, these
data indicate that TxA2 is an important mediator of reversible
renal vasoconstriction in both human and murine lupus nephri-
tis. However, the effects of more prolonged thromboxane
receptor blockade on the progression of renal disease in SLE is
not known.
In the present study, we administered the specific thrombox-
ane receptor antagonist GR32191 [17, 181 to MRL-lpr/lpr mice
for eight weeks beginning at 12 weeks of age. As controls, we
studied congenic MRL-+/+ mice which lack the lpr gene but,
nevertheless, develop a late onset, mild form of autoimmunity
[19]. In these studies, treatment with GR32191 improved renal
hemodynamic function, reduced proteinuria, and decreased
urinary excretion of TxB2. In addition, chronic thromboxane
receptor blockade markedly reduced the severity of renal
histomorphologic abnormalities and caused a modest reduction
in glomerular IgG deposition. These data suggest that TxA2 not
only mediates reversible renal vasoconstriction in lupus nephri-
tis, but is also an important mediator of renal injury.
Methods
Animals
MRL-lpr/lpr and MRL-+/+ mice were originally obtained
from the Jackson Laboratory (Bar Harbor, Maine, USA).
These animals were subsequently maintained and bred in the
973
Received for publication July 15, 1991
and in revised form October 17, 1991
Accepted for publication October 18, 1991
0 1992 by the International Society of Nephrology
974 Spurney et a!: TxA2 receptor blockade in murine lupus
animal facility of the Durham VA Medical Center. In some
studies, normal outbred mice (Charles Rivers Laboratories,
Wilmington, Massachusetts, USA) were used to evaluate the
efficacy of thromboxane receptor blockade. All animals were
given standard laboratory chow and tap water ad libitum.
Experimental protocol
Beginning at 12 weeks of age, MRL-lpr/lpr mice were ran-
domized to receive either 40 mg/kg/day of the specific throm-
boxane receptor antagonist GR32191 [17, 181 ([1R-[la(Z),213,3/3,
5c1] -( + )-7- [5- ([1,1' -biphenyl] -4-ylmethoxy)-3 -hydroxy-2-(1-
piperidinyl)cyclopentyl]-4-heptonoic acid; Glaxo Inc., UK) or its
vehicle (distilled water) by twice daily subcutaneous injection.
Eleven animals were randomized to GR32191 treatment and 10
animals served as vehicle controls. In both groups, one animal
died at 18 weeks of age leaving a total of 10 GR32191 treated mice
and nine vehicle controls for study. At 12 and 20 weeks of age,
blood samples were collected for measurement of anti-DNA
antibody levels. Also, at 20 weeks of age, mice were placed in
metabolic cages and urine collected for 24 hours. The urine was
chilled throughout the collection period and then stored at —70C
until TxB2 and protein were quantitated as described below.
Following the urine collections, both GFR and CPAH were mea-
sured in GR32191 treated mice and vehicle controls. Renal hemo-
dynamic studies were typically performed between two and six
hours after the last dose of GR32191 or vehicle. After GFR and
CPAN measurements, mice were sacrificed and kidneys were
removed for histologic study, for extraction of RNA, and for
measurement of renal thromboxane production as described be-
low. As additional controls, a group of untreated 20-week-old
MRL-+/+ mice (N 9) were studied using a protocol identical to
that described above.
Renal hemodynamic studies
GFR and CPAH were measured in mice as previously de-
scribed [201. On the day of study, animals were anesthetized
with 0.04 mglg pentobarbital, and a polyethylene catheter (PE
90) was inserted into the trachea to facilitate spontaneous
ventilation. The left carotid artery and left jugular vein were
cannulated with polyethylene catheters (PE-lO) for intravenous
infusions, to monitor mean arterial pressure (MAP) (Gould-
Statham strain gauge), and to allow intermittent sampling of
arterial blood. Following surgery, normal saline (2.0% of the
body weight) was infused intravenously over 20 minutes to
replace surgical losses. A priming dose of carboxyl-'4C-inulin
and glycyl-3H-PAH was given, followed by infusion of pento-
barbital, carboxyli4Cinulin, and glycyl-3H-PAH in normal
saline at a rate of 25 l/minute/l00 g body wt. The bladder was
cannulated via a suprapubic incision with a PE-50 catheter.
After 30 minutes of equilibration, renal function was measured
during two consecutive, 30-minute clearance periods. Car-
boxyl-'4C-inulin, and glycyl-3H-PAH in plasma and urine were
measured in a liquid scintillation counter (Nuclear Chicago-TM
Analytical Inc., Elk Grove, Illinois, USA). Clearances were
calculated using standard formulas.
To evaluate the effectiveness of thromboxane receptor block-
ade achieved by GR32191, we assessed the ability of GR32191
to block the renal vasoconstriction caused by the thromboxane
agonist U466l9 [21] (Cayman Chemical Inc., Ann Arbor, Mich-
igan, USA). In these studies, normal outbred mice (N = 10)
b
Dose of GR32191
Fig. I. Blockade of renal throinboxane receptors by various doses of
GR32191. The ability of the thromboxane receptor antagonist GR32191
to block the renal vasoconstriction produced by the thromboxane
agonist U46619 was evaluated in normal mice. Animals received
various doses of GR32191 or vehicle by twice daily subcutaneous
injection. After three days of treatment, renal hemodynamic function
was measured at baseline and during infusion of 10 j.g/kg/min U46619.
Results of the GFR measurements during infusion U46619 are pre-
sented as percent baseline GFR. N represents the number of animals in
each group.
received either GR32 191 or vehicle by twice daily subcutaneous
injection. After three days of treatment, renal hemodynamic
function was measured using a preparation procedure identical
to that outlined above. Following two baseline clearance peri-
ods, 10 rg/kg/min of U46619 was infused intravenously. After
20 minutes, renal hemodynamic function was measured while
infusion of the thromboxane agonist was continued. Results of
these studies are shown in Figure 1. In vehicle treated controls,
U46619 reduced GFR from 9.6 1.1 to 0.1 0.1 ml/min/kg;(P
<0.005) and CPAH from 33.2 7.4 to 0,4 0.3 mI/mm/kg (P
<0.005). In contrast, in mice given 40 mg/kg/day GR32191, both
GFR [10.4 1.6 (baseline) vs. 11.4 0.7 ml/min/kg (U46619);P = NS] and CPAH [37.1 4.6 (baseline) vs. 36.8 7.6
ml/min/kg (U46619); P — NS] were similar before and during
administration of the thromboxane agonist. Furthermore, this
effect persisted for at least 10 hours after the last dose of
GR32191. Lower doses of the thromboxane receptor antagonist
only partially blocked the renal vasoconstriction produced by
U46619 (Fig. 1). Because of the long lasting thromboxane
receptor blockade achieved with 40 mg/kg/day GR32191, this
dose was chosen for the chronic treatment studies.
In addition, to determine the effectiveness of thromboxane
receptor blockade after eight weeks of treatment with GR32 191,
three GR32 191 treated MRL-lpr/lpr mice and three vehicle
treated MRL-lpr/Ipr animals were given 10 g/kg/min U46619
after measurement of baseline renal hemodynamics. In MRL-
lpr/lpr animals given vehicle, U46619 reduced GFR from 7.6
2.2 to 1.3 1.2 mI/kg/mm (P <0.05) and CPAH from 32.8 4.8
to 4.1 4.0 mI/kg/mm (P < 0.05). In contrast, in GR32191
treated MRL-lpr/lpr mice, U466l9 had no significant effect on
either GFR [9.0 1.6 (baseline) vs. 8.3 2.1 ml/mmn/kg
(U46619); P NS] or CPAH [36.4 4.3 (baseline) vs. 36.6 8.0
mI/mm/kg (U466l 9)].
E
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Preparation of renal cortical homogenates
Following the renal hemodynamic studies, the left kidney
was rapidly removed and placed in Kreb's Henseleit buffer at
4°C. The kidney was bisected on ice, and a central slice
obtained. Cortex was separated from the medulla by macrodis-
section. Portions of cortex were uniformly minced with a razor
blade and suspended in 2 ml of buffer. Cortical suspensions
were incubated for 30 minutes on a shaking platform at 37°C in
5% CO2 and 95% 02. Samples were then centrifuged at 2000
rpm for 10 minutes at 4°C and supernatants stored at —70°C.
Eicosanoids in unextracted samples were measured by radio-
immunoassay (RIA) as described below. The pellet was resus-
pended in buffer and the protein concentration determined
using the Coomassie Brilliant Blue dye-binding assay [22].
Eicosanoid measurements
High performance liquid chromatography (HPLC). Urinary
thromboxane metabolites were extracted and separated by
HPLC as described previously [23]. Samples were acidified to
pH 3 to 3.5 and then applied to Sep-Pak C18 columns (Waters
Associates, Milford, Massachusetts, USA) preconditioned with
methanol and water. After washing the column with a 1:9
solution of acetonitrile and water, samples were eluted with
ethyl acetate. Samples were evaporated to dryness under
nitrogen and then reconstituted in a 1:3 solution of acetonitrile
and 5.0 m phosphoric acid.
To separate thromboxane metabolites in urine, a Pecosphere
HS3-Cl8 cartridge (Perkin-Elmer Corp., Norwalk, Connecti-
cut, USA) was used. Samples, unlabeled standards (Advanced
Magnetics Inc., Cambridge, Massachusetts), and tritiated stan-
dards (New England Nuclear, Boston, Massachusetts, USA)
were injected onto the column and eluted by a linear gradient
from 100% 2.5 mr'vi trifluoroacetic acid (Aldrich, Milwaukee,
Wisconsin, USA) to 100% acetonitrile (Fisher Scientific, Fair-
lawn, New Jersey, USA) over 10 minutes at a flow rate of 3.0
mI/mm. Elution of thromboxane metabolites from the column
was monitored by absorbance at a wavelength of 195 nm with a
programmable multiwavelength ultraviolet spectrophotometer
(Waters Associates). All separations were performed at ambi-
ent temperature. Specific eluate fractions were collected based
on the retention time of TxB2 standard. The TxB2 fraction was
dried under a stream of nitrogen and resuspended in radioim-
munoassay (RIA) buffer. Concentrations of TxB2 were then
quantitated by RIA as described below. Recoveries of TxB2
ranged from 60 to 80%.
Radioimmunoassays. Antisera and unlabeled standards were
purchased from Seragen Inc. (Boston, Massachusetts, USA).
For measurement of TxB2, unknowns (measured in duplicate)
and standards (measured in triplicate) were incubated with a
mixture of antisera and a known amount of tritiated standard
overnight at 4°C. After incubation, free eicosanoid was ad-
sorbed with dextran-coated charcoal. Sample concentrations
were determined by a standard curve in which the logarithm of
the concentration was plotted against the logit of the B/Bo
value. The results for urinary TxB2 are expressed as pg124 hr.
For renal cortical homogenates, results are expressed as pgl
mm/mg protein.
Urinary protein excretion. Following the 24-hour urine col-
lections, an aliquot of urine was removed for measurement of
protein concentration using the Coomassie Brilliant Blue dye-
binding assay [22]. Results for urinary protein excretion are
expressed as mg/24 hours. Proteinuria was considered to be
present if urinary protein excretion exceeded 6.9 mg/24 hr
(mean 2 SD of the mean for normal MRL-+/+ mice). This
amount of proteinuria is similar to previously reported values
for normal male mice at four to five months of age [24].
Histologic studies
Light microscopy. Following the renal hemodynamic studies,
a portion of kidney was removed and fixed with 10% buffered
formalin and then stained with hematoxylin and eosin. The
slides were reviewed by a pathologist (PR) blinded to the
treatment group. At least 20 glomeruli were evaluated in every
kidney tissue section. Individual abnormalities in tissue sec-
tions were graded on a scale from 0 to 4+ where 0 was no
abnormality, and 1+, 2+, 3+, and 4+ represented mild, mod-
erate, moderately-severe, and severe abnormalities, respec-
tively. For glomeruli, the following specific abnormalities were
graded separately: hypercellularity, crescents, necrosis, and
hyaline thrombi. For tubulointerstitial areas and vessels, indi-
vidual scores were obtained for the severity of interstitial
inflammatory cell infiltrates and severity of vasculitis. In gb-
meruli, a semiquantitative score of 1 represented focal segmen-
tal changes and a score of 4 represented a diffuse global
process. In tububointerstitial areas and vessels, a semiquantita-
tive score of 1 represented mild focal abnormalities and a score
of 4 represented severe diffuse changes. As an index of the
overall severity of renal histopathology, a histopathobogic score
was also calculated for each animal by summing the grades for
each individual abnormality (maximum score 24).
Direct immunofluorescence. Portions of right kidney were
coated with 7.5% gelatin, allowed to harden on ice, and then
immersed in 2-methylbutane at —120°C for 60 seconds and
stored at —70°C until sectioning. Murine IgG, IgA, 1gM, and C3
were identified by direct iminunofluorescence using standard
techniques. Briefly, frozen sections were fixed in acetone, air
dried, and then treated for 45 minutes with fluoresceinated goat
anti-mouse C3, IgG, 1gM, or IgA (Cappel Laboratories, West
Chester, Pennsylvania, USA). Sera were diluted in phosphate
buffered saline (pH 7.2 to 7.4) with 1% bovine serum albumin to
a dilution that yielded the optimum specific fluorescence with
the least amount of background. Slides prepared in this fashion
were reviewed by a pathologist (FS) blinded to treatment group.
Whole kidney sections were examined for deposition of im-
mune complexes in glomeruli, vessels, and tububointerstitial
areas. Tissue sections were evaluated for the pattern of immune
complex deposition and the percentage of structures involved.
The severity of the immune deposits was graded using a
semiquantitative scale where 0 was no abnormality and 1+, 2+,
3+, and 4+ represented increasingly severe immune complex
deposition.
Preparation of RNA and Northern analysis. Freshly excised
pieces of right renal cortex were frozen in liquid nitrogen and
stored at —70°C. RNA was isolated using the guanidinium
isothiocyanate/cesium chloride method [25]. Twenty-five mi-
crograms of total cellular RNA was denatured at 56°C in 50%
formamide and separated by electrophoresis in an 18% formal-
dehyde, 1.0% agarose gel. The RNA was transferred onto a
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nylon filter (Schleicher and Schuell, Keene, New Hampshire,
USA) by capillary action. Filters were hybridized with eDNA
probes for murine IL1-/3 1261 and /3-actin [27]. Probes were
32P-labeled using the random primer method [281. Hybridization
was carried out overnight at 42°C. Filters were then washed
with lx SSC and 0.2x SSC with 1% SDS at room temperature
and 0.2x SSC with 1% SDS at 65°C. After hybridization,
autoradiography was performed using standard techniques. The
resulting Northern blots were analyzed by densitometry and
mRNA levels quantitated by measuring the areas under the
densitometric peaks. Data are expressed as densitometry units
calculated by dividing the signal for ILl-/3 by the signal for
-actin.
Anti-DNA antibody measurement. Anti-DNA antibody levels
were measured by ELISA as previously described [29]. Briefly,
native calf thymus DNA (Sigma Chemical Co., St. Louis,
Missouri, USA) was treated with purified SI nuclease (Sigma)
to prepare double stranded DNA (d5DNA). Single stranded
DNA (ssDNA) was obtained by boiling for 10 minutes followed
by rapid immersion in ice. Immunlon I 96-well polystyrene
microtiter plates (Dynatech Laboratories, Alexandria, Virginia,
USA) were coated with either ssDNA or dsDNA at 5 p.g/ml for
18 hours at 37°C. The plates were then washed with PBS
containing 0.05% Tween 20 (PBS-T). Serial dilutions of sera in
PBS-T were added to the wells and incubated for 90 minutes at
room temperature. The plates were again washed with PBS-T,
followed by the addition of peroxidase-conjugated rabbit anti-
mouse IgG (7S) (Bionetics, Kensington, Maryland, USA) di-
luted 1/200 in PBS-T. After a 60-minute incubation, plates were
washed with PBS-T. The plates were then incubated for 35
minutes with a substrate solution of 0.015% N,N,N',N'-tetra-
methylbenzidine (Organon, Teknika, Oklahoma City, Okla-
homa, USA) and 0.03% H202 in 0.1 M citrate buffer, pH 4. The
absorbances were measured at 380 nm using a Titertek Multi-
skan Plus (Flow Laboratories). Data are expressed as optical
density (OD) units calculated as 100 x OD at 380 nm. The
specificity of this antibody for y chains is shown by minimal
reactivity with the BALB/c 1gM myeloma MOPC lO4E.
Measurement of serum IgG and 1gM levels. Total serum IgG
and 1gM were determined by ELISA using previously described
methods [301. Briefly, 96-well polystyrene microtiter plates
(Dynatech Laboratories) were coated with goat anti-mouse
polyvalent immunoglobulins (Sigma Chemical Co.) in PBS at 5
g/m1 overnight at 4°C. Plates were blocked with 1% BSA in
PBS prior to the addition of serial dilutions of sera or either
mouse IgG (Sigma Chemical Co.) or 1gM mouse myeloma
protein MOPCIO4E (Bionetics). After incubation for 60 min-
utes, plates were washed and then peroxidase-conjugated goat
anti-mouse IgG or 1gM (Sigma Chemical Co.) were added, The
plates were incubated for 35 minutes with a substrate solution
of 0.015% N,N,N',N'-tetramethylbenzidine (Organon, Tekni-
ka) and 0.015% H202 in 0.1 M citrate buffer, pH 4. The
absorbances were measured at 380 nm using a Titertek Multi-
skan Plus plate reader (Flow Laboratories). Serum concentra-
tions of IgG and 1gM were calculated from linear regression
equations relating either the OD at 380 nm to the log10 (1gM
standard concentration) or OD 380 nm to log10 (1gM standard
concentration).
Table 1. Effects of GR32191 in 20-week-old MRL-lpr/lpr mice
GFR CPAH Proteinuria
mg/24 hoursmi/mm/kg
MRL-lpr/ipr 6.8 1.1 29.9 3.3 18.1 11.6(Vehicle, N = 8)
MRL-lpr/lpr 8.9 0.6k 37.4 2.5° 3.7 l.3(GR32191, N = 9)
MRL-+/+ 9.9 0.5" 40.0 34" 3.5 0.6"
(N = 9)
° P < 0.05 and b P < 0.01 vs. MRL-lpr/ipr mice given vehicle
Statistical analysis
Data are presented as the mean standard error of the mean.
For the hemodynamic studies, data points for each animal
represent the mean of the values measured during two clear-
ance periods. Quantitative data were analyzed by the Shapiro
Wild statistic [31] to determine if the values were distributed
normally, and then assessed for statistical significance using the
Student's t-test or Wilcox rank sum as appropriate. Categorical
classification of renal histopathologic data was assessed for
statistical significance by Cochran-Mantel-Haenszel statistic
[32] using rank scores of the data. Correlations were performed
using linear regression analysis.
Results
To investigate the role of TxA2 in murine lupus nephritis, we
first measured renal hemodynamic function and proteinuria in
20-week-old MRL-lpr/lpr mice after eight weeks of treatment
with the specific thromboxane receptor antagonist GR32 191. As
shown in Table 1, treatment with the thromboxane receptor
antagonist significantly improved GFR, CPAH, and proteinuria
compared to vehicle treated controls. In GR32191 treated
MRL-lpr/lpr mice, renal hemodynamic function and urinary
protein excretion were not significantly different from values in
MRL-+/+ mice of the same age (Table 1). Moreover, by 20
weeks of age, only 10% of the mice given GR32191 had
developed urinary protein excretion rates above the normal
range for MRL-+/+ mice (mean plus two SD) compared to 55%
of the vehicle treated animals (P <0.025).
We next evaluated the effects of CR32191 on renal histopa-
thology. Figure 2 shows representative photomicrographs of
kidneys from MRL-lpr/lpr mice given either vehicle (Fig. 2A) or
GR32191 (Fig. 2B). By 20 weeks of age, kidneys from vehicle
treated mice typically showed a severe proliferative glomerulone-
phritis associated with glomerular crescent formation, hyaline
thrombi, mononuclear inflammatory cells in tubulointerstitial ar-
eas, and often a necrotizing vasculitis. Renal histomorphologic
abnormalities were much less severe in kidneys from GR32191
treated mice (Fig. 2B and Table 2). There was a statistically
significant reduction in the severity of interstitial inflammatory cell
infiltrates and hyaline thrombi in mice receiving the thromboxane
receptor antagonist. In addition, glomerular crescent formation
and severity of vasculitis tended to be reduced in GR32191 treated
mice, As a result of these differences, the overall histopathologic
score in mice receiving the thromboxane receptor antagonist was
significantly lower than vehicle treated animals (4.7 0.5 vs. 8.4
1.5; P = 0.016). Nevertheless, renal histomorphology remained
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Fig. 2. Effect ofGR32191 on renal histopathology. A. A proliferative glomerulonephritis with crescent formation and interstitial inflammation is
seen in this kidney from a vehicle treated control animal. B. Mild glomerular hypercellularity and scant interstitial inflammatory cell infiltrates are
seen in this kidney from a GR32191 treated mouse. Sections were stained with hematoxylin and eosin and the magnification is 190X.
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a P = 0.006, b P = 0.022, and P = 0.078 vs. vehicle controls
abnormal in animals receiving the thromboxane receptor antago-
nist, The overall histopathologic score in GR32191 treated MRL-
lpr/lpr mice was still significantly increased compared to MRL-
+1+ mice of the same age (1.6 0.2; P = 0.001).
Kidneys were also examined for immune deposits by direct
immunofluorescence. In both GR32191 treated mice and vehicle
controls, deposits of IgG, 1gM, IgA, and C3 were found in 75 to
100% of the glomeruli. In both groups, glomerular immune
deposits tended to localize in the mesangium but were also
found in capillary loops. This mesangiocapillary pattern of
immune complex deposition was similar for immunoglobulins
and complement, and was most intense for IgG and C3. Focal
deposits of IgG, 1gM, IgA and C3 were also seen in approxi-
mately 50% of the medium sized to large vessels in kidneys
from both GR32191 treated mice and vehicle controls. In
addition, there were rare deposits of 1gM or C3 in peritubular
areas of most animals. Representative immunofluorescence
studies for glomerular IgG deposits are shown in Figure 3. In
vehicle treated animals (Fig. 3A), heavy deposits of IgG were
found in both mesangium and capillary loops. However, subtle
differences were detected in mice receiving the thromboxane
receptor antagonist (Fig. 3B). In mice given GR32191, deposi-
tion of IgG in capillary loops was reduced compared to vehicle
controls, although deposits of IgG were still found in mesangial
areas and were of equivalent magnitude. Overall, there was a
reduction in the intensity of the glomerular deposits of IgG in
GR32191 treated mice as reflected in the significantly lower
semiquantitative score for IgG in these animals (Table 3).
Glomerular deposits of IgA and 1gM also tended to be lower in
animals given the thromboxane receptor antagonist, but C3 was
similar in both groups (Table 3). There were no differences in
the intensity of the immune deposits in either vessels or
peritubular areas between GR32191 treated mice arid vehicle
controls.
The beneficial effects of GR32191 on renal function, protein-
uria, and renal histopathology were associated with a decrease
in renal production of TxB2. As shown in Table 4, treatment
with GR32191 reduced urinary TxB2 excretion in MRL-lprllpr
mice to levels similar to those in MRL-+/+ mice. The same
trend was observed for thromboxane production by renal
cortical homogenates (Table 4). However, in contrast to urinary
TxB2 excretion, thromboxane production by renal cortices
remained significantly increased in both groups of MRL-lprllpr
mice compared to MRL-+/+ controls. In these MRL-lpr/lpr
mice, there was a direct correlation between thromboxane
production by cortical homogenates and the severity of hyaline
thrombi in glomeruli (r = 0.82,P <0.001) as well as the severity
of interstitial inflammation (r 0.49, P <0.05).
Anti-DNA antibody levels in sera were measured in ten
MRL-lpr//pr mice from each treatment group at 12 weeks of age
Vehicle
(N =9)
GR32191
(N = 10)
Table 2. Frequency of individual scores for specific histologic abnormalities in MRL-lprllpr mice
Glomerular abnormalities . .Interstitial
inflammation
.
Severity of
vasculitisCrescents Thrombi
-__Necrosis Cellularity
<1 1 <1 1 <1 2 >2 2 >2 2 >2
'-
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Fig. 3. Effects of GR32191 on glomerular
deposition of IgG. A. Heavy deposits of IgG
are seen in both mesangium and capillary
loops of this kidney from a vehicle control. B.
A kidney from a GR32l91 treated animal.
Deposits of IgG are present in the mesangial
areas but deposition of IgG in the capillary
loops is reduced compared to vehicle
controls. Immune deposits were detected by
direct immunofluorescence and the
magnification is 276x.
Semiquantitative score
Vehicle GR32191
lgG 3.5 0.2 2.6 o.2
IgA 2.0 0.2 1.7 0.2
1gM 2.4 0.3 2.0 0.2
C3 3.4 0.1 3.5 0.2
as well as in eight GR32 191 treated and seven vehicle treated
MRL-lpr/Ipr mice at 20 weeks of age. As shown in Table 5,
serum autoantibodies to both ssDNA and dsDNA increased
significantly between 12 and 20 weeks of age in both groups of
MRL-lpr/lpr mice. There were no significant differences in
anti-DNA antibody levels between GR32191 treated mice and
vehicle controls of similar age. Furthermore, anti-DNA anti-
body levels in MRL-lprllpr mice of both groups were signifi-
cantly higher than levels of anti-DNA antibodies to either
Urinary TxB2
mg/24 hour
Cortical TxB2
pg/mm/mg protein
MRL-lpr/lpr 747 155ac + 29b.c(Vehicle, N = 9)
MRL-lpr/lpr 292 37 63 I1
(GR32191, N 10)
MRL-+/+ 272 51 16 2(N = 9)
ssDNA or dsDNA in MRL-+/+ mice (N = 9) of the same age
(ssDNA 17 1 OD and dsDNA 2 1 OD units; P <0.005). In
seven 20-week-old MRL-lpr/lpr mice from each treatment
group, serum was available for measurement of total IgG and
1gM levels. In these mice, there were no significant differences
in total IgG levels [17.8 10.1 (GR32191) vs. 25.4 8.7
(vehicle) mg/mi; P NS] or total 1gM levels [0.76 0.21
Table 3. Glomerular immune deposits in 20-week-old MRL-lpr/lpr
mice
Table 4. Effect of GR32191 on TxB2 production in 20-week-old
MRL-lpr/lpr mice
P < 0.02 vs. vehicle controls
°P < 0.005 orb P < 0.10 vs. GR32191 treated MRL-lprllpr mice
c P < 0.01 vs. MRL-+/+ mice
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Table 5. Anti-DNA antibody levels in sera of MRL-Ipr/lpr mice
Age
Anti-ssDNA Anti-dsDNA
Vehicle GR32191 Vehicle GR32191
12 weeks 19 5.3 14 3.6 8.4 1.7 8.1 2.5
20 weeks 64 l2 63 j4 19 4.3" 22 62b
Data are presented as OD units calculated as 100 x OD at 380 nrn.
a P < 0.005 vs. 12-week-old MRL-lprllpr mice
b P < 0.025 vs. 12-week-old MRL-lprI/pr mice
(GR32 191) vs. 0.62 0.09 (vehicle) mg/mI; P = NS] after eight
weeks of treatment with the thromboxane receptor antagonist.
To assess another marker of disease activity, we studied the
effects of chronic thromboxane receptor blockade on steady
state levels of IL-1/3 mRNA in renal cortices of MRL mice. As
reported previously by Boswell et al [33], we also found that
steady state levels of IL-l/3 mRNA were elevated in kidneys of
MRL-lprllpr mice with nephritis, but were not detected in renal
cortices of MRL-+/+ controls (Fig. 4A). Furthermore, we
found no significant differences in steady state levels of IL-l13
mRNA in five kidneys from MRL-lprllpr mice given GR32191
(506 0.096 densitometry units) compared to five kidneys from
vehicle controls (0.413 0.143 densitometry units).
Discussion
These studies demonstrate that chronic thromboxane recep-
tor blockade has profound effects on renal disease in MRL-lpr/
lpr mice. Treatment with GR32191 improved renal hemody-
namic function, decreased proteinuria, and reduced the severity
of the renal histologic abnormalities as reflected in the number
of hyaline thrombi in glomeruli, interstitial inflammation, gb-
merular crescent formation, and severity of vasculitis. To-
gether, these data suggest that TxA2 is an important mediator of
renal dysfunction and injury in murine lupus nephritis.
Both GFR and CPAH were restored to levels not significantly
different from MRL-+/+ controls by treatment with the throm-
boxane receptor antagonist. This effect of chronic thromboxane
receptor blockade contrasts sharply with the effects of acute
administration of GR32191 previously reported [14]. In this
previous study, we found that acute intravenous infusions of
GR32191 restored renal hemodynamic function to normal in
16-week-old MRL-lpr/lpr mice in the early stages of nephritis
but was much less effective in 20-week-old animals with ad-
vanced renal disease [14]. The lack of response in 20-week-old
MRL-lpr/lpr mice was attributed to irreversible renal damage.
The more substantial improvement in renal hemodynamics
observed in the present study supports the notion that chronic
thromboxane receptor blockade not only reversed renal vaso-
constriction in MRL-lprllpr mice but also reduced renal injury.
Chronic thromboxane receptor blockade also reduced the
severity of the renal histologic abnormalities. Inhibiting the
actions of TxA2 in the kidney may decrease renal inflammation
and injury by a variety of direct and indirect mechanisms. By
reducing thromboxane-induced platelet aggregation, GR32191
could diminish platelet release of growth factors and therefore
decrease cellular proliferation [8]. In this regard, platelet-
derived growth factor (PDGF) binds to mesangial cells in a
specific manner and stimulates proliferation of mesangial cells
[34]. Indeed, platelet depletion reduces glomerular cell prolif-
eration in immune complex nephritis induced by anti-mesangial
cell antibodies in rats [8]. Moreover, platelet-derived mediators
may stimulate chemotaxis and increase production of other
inflammatory compounds [10]. Furthermore, chronic throm-
boxane receptor blockade might directly affect immune func-
tion by decreasing the stimulatory effects of TxA2 on lympho-
cyte proliferation [34, 35] or reducing thromboxane-induced
polymorphonuclear cell adhesiveness [36].
In addition to the effects to GR32191 on renal hemodynamic
function and renal histomorphology, urinary protein excretion
was reduced by treatment with GR32191. Although this de-
crease in proteinuria may reflect a lesser degree of glomerular
damage in GR32191 treated mice, TxA2 may have more direct
effects on urinary protein excretion. In nephrotoxic serum
nephritis in the rat [37] and in lupus mice [13], proteinuria
correlates directly with thromboxane production by the kidney.
Although urinary protein excretion and renal thromboxane
production maybe independent markers of glomerular injury, it
is possible that TxA2 may influence the severity of proteinuria
by directly affecting glomerular capillary permeability, as sug-
gested Remuzzi et al [38]. In support of this hypothesis,
thromboxane synthase inhibition prevents the increase in renal
thromboxane production characteristic of adriamycin nephrosis
in rats and reduces proteinuria, although glomerular histologic
abnormalities are minimal in adriamycin treated animals [38].
Moreover, in an animal model of complement-mediated glomer-
ular injury, short-term treatment with thromboxane synthase
inhibitors improves glomerular filtration and reduces protein-
uria without reducing the severity of the glomerular histologic
abnormalities [39].
The beneficial effects of GR32191 in MRL-lpr/lpr mice were
associated with a significant reduction in glomerular deposits of
IgG. Immune complex deposition plays a key role in the
pathogenesis of renal disease in SLE [19, 40]. Within the
glomerulus, hydraulic pressure, glomerular capillary permeabil-
ity, and immune complex size or charge may influence the
severity and localization of immune complexes [41]. Because
thromboxane receptor blockade reduces glomerular capillary
and transcapillary hydraulic pressures in other thromboxane-
dependent renal diseases [421, it is possible that intraglomerular
hemodynamics in lupus mice were similarly improved by
GR32191. Inhibition of platelet aggregation by GR32191 may
also indirectly affect gbomerular capillary permeability by pre-
venting platelet release of vasoactive compounds which may
enhance immune complex deposition [41, 43]. Indeed, experi-
mental depletion of platelets decreases gbomerular deposition of
immune complexes during serum sickness in rabbits [41].
Nevertheless, the reduction in the glomerular IgG deposition in
GR32 191 treated mice was modest compared with the effects of
treatment on renal hemodynamics, proteinuria, and renal his-
topathology. In this context, it seems unlikely that this small
decrease in glomerular deposits of IgG accounted for the
dramatic effects on these other aspects of nephritis in MRL-lpr/
lpr mice.
Treatment with GR32191 also reduced excretion of unmetab-
olized, native TxB2 in urine. Excretion of unmetabolized,
native TxB2 in urine may reflect thromboxane production by
the kidney, and has been used a marker of renal thromboxane
production in vivo [44]. Because GR32191 does not affect
phospholipase A2, cyclooxygenase, or thromboxane synthase
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Fig. 4. Effect of GR32191 on ILI-/3 mRNA
transcripts in renal cortices of MRL mice.
Twenty-five micrograms of total RNA isolated
from renal cortices of 20-week-old MRL-+/+
mice (lanes 1—2), MRL-lpr/lpr mice treated
with GR32191 (lanes 3—4), and MRL-lprllpr
mice treated with vehicle (lanes 5—6) were
separated on 1% agarose gels. A. The filter
was hybridized to the cDNA probe for murine
ILI-f3. Steady state levels of mRNA were
similarly enhanced in both groups of MRL-lpr/
lpr mice compared to MRL-+/+ animals. B.
The filter was rehybridized to the f3-actin
probe.
activity 117], the reduction in urinary TxB2 excretion is likely
related to an indirect effect of the thromboxane receptor antag-
onist on TxA2 production. Although the cellular sources of
enhanced thromboxane production in lupus nephritis are not
known, infiltrating inflammatory cells and platelets can produce
TxA2, The decrease in intrarenal thrombosis and presumably
intrarenal platelet aggregation as well as the reduction in renal
inflammation may both explain the decrease in urinary throm-
boxane excretion. In support of this hypothesis, there were
significant direct correlations between TxB2 production by
renal cortical homogenates and both the severity of hyaline
thrombi in glomeruli and the number of interstitial inflammatory
cells.
We also investigated the effects of GR32191 on several
markers of disease activity including: anti-DNA antibody titers
in sera, steady state levels of IL-l/3 mRNA in renal cortices,
and total serum IgG and 1gM levels. However, chronic throm-
boxane receptor blockade had no significant effect on these
markers of disease activity in MRL-lprllpr mice. Antibody titers
to both ssDNA and dsDNA as well as total IgG and 1gM levels
in MRL-lpr/lpr mice were not significantly affected by treatment
with the thromboxane receptor antagonist. Furthermore,
steady state levels of IL-lJ3 mRNA were similarly enhanced in
renal cortices of MRL-lpr/lpr mice given either GR32191 or
vehicle.
Previous attempts at suppressing renal thromboxane synthe-
sis have not had beneficial effects on nephritis in lupus mice [13,
45]. For example, cyclooxygenase inhibition sufficient to re-
duce platelet cyclooxygenase activity by 90% did not improve
survival or prevent the development of renal disease in two
murine models of SLE [13]. Selective inhibition of thrombox-
ane synthase also had no significant effect on proteinuria or
survival in lupus mice despite a 40% reduction in urinary
excretion of thromboxane metabolites 145]. The poor response
to therapy in these studies may, in part, reflect incomplete
suppression of renal thromboxane synthesis. Indeed, renal
thromboxane production was unaffected by cyclooxygenase
inhibition in the study cited [13]. Moreover, because urinary
thromboxane metabolites may be derived from both renal and
extrarenal sources in lupus nephritis [14, 15], a 40% reduction in
urinary excretion of thromboxane metabolites may not reflect
effective suppression of TxA2 synthesis in the kidney. How-
ever, even effective inhibition of renal TxA2 production by
specific thromboxane synthase inhibitors does not impair syn-
thesis of prostaglandin endoperoxides which may act as ago-
nists at the thromboxane receptor and blunt the efficacy of
therapy 1461. Furthermore, although cyclooxygenase inhibition
blocks synthesis of prostaglandin endoperoxides, it also re-
duces production of vasodilator prostaglandins such as prosta-
glandin E2 and prostacyclin which may help counteract the
renal hemodynamic effects of vasoconstrictor eicosanoids in
SLE [15, 47]. In contrast, thromboxane receptor antagonists
effectively block the physiologic actions of both TxA2 and
prostaglandin endoperoxides at their shared receptor [46].
Therefore, thromboxane receptor antagonists may offer some
therapeutic advantage over both cyclooxygenase inhibitors and
thromboxane synthase inhibitors for the treatment of throm-
boxane dependent disorders.
In summary, chronic thromboxane receptor blockade mark-
edly altered the course of renal disease in the MRL-lprllpr
murine model of lupus nephritis. Treatment with GR32191
improved renal hemodynamic function, decreased proteinuria,
and reduced the severity of the renal histologic abnormalities.
These data indicate that TxA2 plays an important role in the
pathogenesis of renal dysfunction and injury in murine lupus
nephritis and suggest that chronic thromboxane receptor block-
ade may be a useful adjunct to currently available treatments
for renal disease in patients with SLE.
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